In the context of treatment, as has been previously reported, IL-17 inhibition has been proven to be effective in conditions like AS and PsA, but not in IBD, whereas targeting IL-23 has shown potential benefits in IBD but lacks similar efficacy in AS [176]. Here, IL23A is linked to inflammatory bowel disease.